Abstract
Background: This study investigated whether the effectiveness of first-line tyrosine-kinase inhibitors was associated with sites of disease in patients with metastatic renal cell carcinoma (mRCC). Methods: A retrospective cohort of consecutive mRCC patients receiving first-line sorafenib (SO) or sunitinib (SU) was analyzed. Results: In total, 203 patients received SO and 99 SU. In patients with liver metastasis, SU was associated with a 18% higher risk of time-to-treatment failure (TTF), and a 39% higher risk of death than SO: conversely, patients without liver metastases who received SU showed a 46% decreased risk of TTF and 62% decreased risk of death. Conclusions: mRCC patients with liver metastases treated with first-line SO showed a better outcome compared with SU, while mRCC patients without liver metastases treated with firstline SU showed a better outcome compared with SO.
| Original language | English |
|---|---|
| Pages (from-to) | 59-68 |
| Number of pages | 10 |
| Journal | Therapeutic Advances in Urology |
| Volume | 7 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Apr 27 2015 |
Fingerprint
Keywords
- predictive factors
- renal cell carcinoma
- sites of metastases
- sorafenib
- sunitinib
ASJC Scopus subject areas
- Urology
Cite this
Sites of disease as predictors of outcome in metastatic renal cell carcinoma patients treated with first-line sunitinib or sorafenib. / Grassi, Paolo; Verzoni, Elena; Porcu, Luca; Iacovelli, Roberto; De Braud, Filippo; Procopio, Giuseppe.
In: Therapeutic Advances in Urology, Vol. 7, No. 2, 27.04.2015, p. 59-68.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Sites of disease as predictors of outcome in metastatic renal cell carcinoma patients treated with first-line sunitinib or sorafenib
AU - Grassi, Paolo
AU - Verzoni, Elena
AU - Porcu, Luca
AU - Iacovelli, Roberto
AU - De Braud, Filippo
AU - Procopio, Giuseppe
PY - 2015/4/27
Y1 - 2015/4/27
N2 - Background: This study investigated whether the effectiveness of first-line tyrosine-kinase inhibitors was associated with sites of disease in patients with metastatic renal cell carcinoma (mRCC). Methods: A retrospective cohort of consecutive mRCC patients receiving first-line sorafenib (SO) or sunitinib (SU) was analyzed. Results: In total, 203 patients received SO and 99 SU. In patients with liver metastasis, SU was associated with a 18% higher risk of time-to-treatment failure (TTF), and a 39% higher risk of death than SO: conversely, patients without liver metastases who received SU showed a 46% decreased risk of TTF and 62% decreased risk of death. Conclusions: mRCC patients with liver metastases treated with first-line SO showed a better outcome compared with SU, while mRCC patients without liver metastases treated with firstline SU showed a better outcome compared with SO.
AB - Background: This study investigated whether the effectiveness of first-line tyrosine-kinase inhibitors was associated with sites of disease in patients with metastatic renal cell carcinoma (mRCC). Methods: A retrospective cohort of consecutive mRCC patients receiving first-line sorafenib (SO) or sunitinib (SU) was analyzed. Results: In total, 203 patients received SO and 99 SU. In patients with liver metastasis, SU was associated with a 18% higher risk of time-to-treatment failure (TTF), and a 39% higher risk of death than SO: conversely, patients without liver metastases who received SU showed a 46% decreased risk of TTF and 62% decreased risk of death. Conclusions: mRCC patients with liver metastases treated with first-line SO showed a better outcome compared with SU, while mRCC patients without liver metastases treated with firstline SU showed a better outcome compared with SO.
KW - predictive factors
KW - renal cell carcinoma
KW - sites of metastases
KW - sorafenib
KW - sunitinib
UR - http://www.scopus.com/inward/record.url?scp=84925597560&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84925597560&partnerID=8YFLogxK
U2 - 10.1177/1756287215571809
DO - 10.1177/1756287215571809
M3 - Article
VL - 7
SP - 59
EP - 68
JO - Therapeutic Advances in Urology
JF - Therapeutic Advances in Urology
SN - 1756-2872
IS - 2
ER -